Home Authors Posts by DrugPatentWatch.com Drug Patent Expirations

DrugPatentWatch.com Drug Patent Expirations

19 POSTS 0 COMMENTS

If your reader cannot render the information below, go to http://www.DrugPatentWatch.com/innovation to see the latest expirations body { font-family:Calibri, tahoma, arial, sans-serif;}table { font-size:12px; font-family:Calibri, tahoma, arial, sans-serif; border-collapse:collapse; margin: 0px auto;}.xsnazzy h1, .zsnazzy h1 { margin:0; font-size:1.2em; padding:0 10px 5px 10px; border-bottom:1px solid #444; }.xsnazzy { background: transparent; margin:0 3px;}.xtop, .xbottom { display:block; background:transparent; font-size:1px; }.xb1, .xb2, .xb3, .xb4 { display:block; overflow:hidden; }.xb1, .xb2, .xb3 { height:1px; }.xb2, .xb3, .xb4 { background:#fff; border-left:1px solid #444; border-right:1px solid #444; }.xb1 { margin:0 5px; background:#444; }.xb2 { margin:0 3px; border-width:0 2px; }.xb3 { margin:0 2px; }.xb4 { height:2px; margin:0 1px;}.xboxcontent { display:block; border:0 solid #444; border-width:0 1px; height:auto; }* html .xboxcontent { height:1px; } td { padding:3px; } tr { border:.5pt; background-color:#FFF; }
Who are the leading pharmaceutical patent challengers? A report on
Paragraph IV challenges
ADVERTISE HERE

This newsletter is a free service of DrugPatentWatch
DrugPatentWatch offers comprehensive details on FDA approved drugs, developers, and their patents

Simple flat-rate database subscription plans

Ultimate PlanPremium PlanBasic Plan
One year$1,995 Subscribe$1,795 Subscribe$1,095 Subscribe
One month$525 Subscribe$425 Subscribe$325 Subscribe
48 hours$95 Subscribe$75 Subscribe
Plan comparison    Site tour    Contact

Drug Patent Expirations for Jun 18 2012

TradenameApplicantGeneric NamePatent Number Patent Expiration
EPZICOMViiv Hlthcareabacavir sulfate; lamivudine5,034,394*PEDJun 18, 2012
TRIZIVIRViiv Hlthcareabacavir sulfate; lamivudine; zidovudine5,034,394*PEDJun 18, 2012
ZIAGENViiv Hlthcareabacavir sulfate5,034,394*PEDJun 18, 2012

*Drugs may be covered by multiple patents or regulatory protections. See the DrugPatentWatch database for complete details.


DrugPatentWatch Serves Your Competitive Intelligence Needs

Subscribers have access to valuable datasets, including:
  • Clinical trial information
  • International patent families
  • International patent priority and PCT information
  • Patent maintenance
  • Full-text patent downloads
  • Sales data (top 200 drugs)
  • Paragraph IV challenges
  • Tentative approvals
  • Dynamic search capabilities with data export
  • More…
See the Database Preview and Plan Comparison. Contact Us with any questions.

The above list does not discriminate between dominant and non-dominant patents. Drugs listed above may be protected by additional patents and other regulatory protections. See the DrugPatentWatch database for complete details

DISCLAIMER:
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
All trademarks and applicant names are the property of their respective owners or licensors.

If your reader cannot render the information below, go to http://www.DrugPatentWatch.com/innovation to see the latest expirations body { font-family:Calibri, tahoma, arial, sans-serif;}table { font-size:12px; font-family:Calibri, tahoma, arial, sans-serif; border-collapse:collapse; margin: 0px auto;}.xsnazzy h1, .zsnazzy h1 { margin:0; font-size:1.2em; padding:0 10px 5px 10px; border-bottom:1px solid #444; }.xsnazzy { background: transparent; margin:0 3px;}.xtop, .xbottom { display:block; background:transparent; font-size:1px; }.xb1, .xb2, .xb3, .xb4 { display:block; overflow:hidden; }.xb1, .xb2, .xb3 { height:1px; }.xb2, .xb3, .xb4 { background:#fff; border-left:1px solid #444; border-right:1px solid #444; }.xb1 { margin:0 5px; background:#444; }.xb2 { margin:0 3px; border-width:0 2px; }.xb3 { margin:0 2px; }.xb4 { height:2px; margin:0 1px;}.xboxcontent { display:block; border:0 solid #444; border-width:0 1px; height:auto; }* html .xboxcontent { height:1px; } td { padding:3px; } tr { border:.5pt; background-color:#FFF; }
Journal of Commercial Biotechnology

ADVERTISE HERE

This newsletter is a free service of DrugPatentWatch
DrugPatentWatch offers comprehensive details on FDA approved drugs, developers, and their patents

Simple flat-rate database subscription plans

Ultimate PlanPremium PlanBasic Plan
One year$1,995 Subscribe$1,795 Subscribe$1,095 Subscribe
One month$525 Subscribe$425 Subscribe$325 Subscribe
48 hours$95 Subscribe$75 Subscribe
Plan comparison    Site tour    Contact

Drug Patent Expirations for Jun 8 2012

TradenameApplicantGeneric NamePatent Number Patent Expiration
MOXEZAAlcon Pharms Ltdmoxifloxacin hydrochloride4,990,517*PEDJun 8, 2012
VIGAMOXAlcon Pharms Ltdmoxifloxacin hydrochloride4,990,517*PEDJun 8, 2012

*Drugs may be covered by multiple patents or regulatory protections. See the DrugPatentWatch database for complete details.


DrugPatentWatch Serves Your Competitive Intelligence Needs

Subscribers have access to valuable datasets, including:
  • Clinical trial information
  • International patent families
  • International patent priority and PCT information
  • Patent maintenance
  • Full-text patent downloads
  • Sales data (top 200 drugs)
  • Paragraph IV challenges
  • Tentative approvals
  • Dynamic search capabilities with data export
  • More…
See the Database Preview and Plan Comparison. Contact Us with any questions.

The above list does not discriminate between dominant and non-dominant patents. Drugs listed above may be protected by additional patents and other regulatory protections. See the DrugPatentWatch database for complete details

DISCLAIMER:
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
All trademarks and applicant names are the property of their respective owners or licensors.

If your reader cannot render the information below, go to http://www.DrugPatentWatch.com/innovation to see the latest expirations body { font-family:Calibri, tahoma, arial, sans-serif;}table { font-size:12px; font-family:Calibri, tahoma, arial, sans-serif; border-collapse:collapse; margin: 0px auto;}.xsnazzy h1, .zsnazzy h1 { margin:0; font-size:1.2em; padding:0 10px 5px 10px; border-bottom:1px solid #444; }.xsnazzy { background: transparent; margin:0 3px;}.xtop, .xbottom { display:block; background:transparent; font-size:1px; }.xb1, .xb2, .xb3, .xb4 { display:block; overflow:hidden; }.xb1, .xb2, .xb3 { height:1px; }.xb2, .xb3, .xb4 { background:#fff; border-left:1px solid #444; border-right:1px solid #444; }.xb1 { margin:0 5px; background:#444; }.xb2 { margin:0 3px; border-width:0 2px; }.xb3 { margin:0 2px; }.xb4 { height:2px; margin:0 1px;}.xboxcontent { display:block; border:0 solid #444; border-width:0 1px; height:auto; }* html .xboxcontent { height:1px; } td { padding:3px; } tr { border:.5pt; background-color:#FFF; }
Pharmaceutical Industry Intelligence

ADVERTISE HERE

This newsletter is a free service of DrugPatentWatch
DrugPatentWatch offers comprehensive details on FDA approved drugs, developers, and their patents

Simple flat-rate database subscription plans

Ultimate PlanPremium PlanBasic Plan
One year$1,995 Subscribe$1,795 Subscribe$1,095 Subscribe
One month$525 Subscribe$425 Subscribe$325 Subscribe
48 hours$95 Subscribe$75 Subscribe
Plan comparison    Site tour    Contact

Drug Patent Expirations for Jun 12 2012

TradenameApplicantGeneric NamePatent Number Patent Expiration
LESCOLNovartisfluvastatin sodium5,356,896*PEDJun 12, 2012
LESCOL XLNovartisfluvastatin sodium5,356,896*PEDJun 12, 2012

*Drugs may be covered by multiple patents or regulatory protections. See the DrugPatentWatch database for complete details.


DrugPatentWatch Serves Your Competitive Intelligence Needs

Subscribers have access to valuable datasets, including:
  • Clinical trial information
  • International patent families
  • International patent priority and PCT information
  • Patent maintenance
  • Full-text patent downloads
  • Sales data (top 200 drugs)
  • Paragraph IV challenges
  • Tentative approvals
  • Dynamic search capabilities with data export
  • More…
See the Database Preview and Plan Comparison. Contact Us with any questions.

The above list does not discriminate between dominant and non-dominant patents. Drugs listed above may be protected by additional patents and other regulatory protections. See the DrugPatentWatch database for complete details

DISCLAIMER:
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
All trademarks and applicant names are the property of their respective owners or licensors.

If your reader cannot render the information below, go to http://www.DrugPatentWatch.com/innovation to see the latest expirations body { font-family:Calibri, tahoma, arial, sans-serif;}table { font-size:12px; font-family:Calibri, tahoma, arial, sans-serif; border-collapse:collapse; margin: 0px auto;}.xsnazzy h1, .zsnazzy h1 { margin:0; font-size:1.2em; padding:0 10px 5px 10px; border-bottom:1px solid #444; }.xsnazzy { background: transparent; margin:0 3px;}.xtop, .xbottom { display:block; background:transparent; font-size:1px; }.xb1, .xb2, .xb3, .xb4 { display:block; overflow:hidden; }.xb1, .xb2, .xb3 { height:1px; }.xb2, .xb3, .xb4 { background:#fff; border-left:1px solid #444; border-right:1px solid #444; }.xb1 { margin:0 5px; background:#444; }.xb2 { margin:0 3px; border-width:0 2px; }.xb3 { margin:0 2px; }.xb4 { height:2px; margin:0 1px;}.xboxcontent { display:block; border:0 solid #444; border-width:0 1px; height:auto; }* html .xboxcontent { height:1px; } td { padding:3px; } tr { border:.5pt; background-color:#FFF; }
Journal of Commercial Biotechnology

ADVERTISE HERE

This newsletter is a free service of DrugPatentWatch
DrugPatentWatch offers comprehensive details on FDA approved drugs, developers, and their patents

Simple flat-rate database subscription plans

Ultimate PlanPremium PlanBasic Plan
One year$1,995 Subscribe$1,795 Subscribe$1,095 Subscribe
One month$525 Subscribe$425 Subscribe$325 Subscribe
48 hours$95 Subscribe$75 Subscribe
Plan comparison    Site tour    Contact

Drug Patent Expirations for Jun 10 2012

TradenameApplicantGeneric NamePatent Number Patent Expiration
IMITREXGlaxosmithklinesumatriptan5,705,520*PEDJun 10, 2012

*Drugs may be covered by multiple patents or regulatory protections. See the DrugPatentWatch database for complete details.


DrugPatentWatch Serves Your Competitive Intelligence Needs

Subscribers have access to valuable datasets, including:
  • Clinical trial information
  • International patent families
  • International patent priority and PCT information
  • Patent maintenance
  • Full-text patent downloads
  • Sales data (top 200 drugs)
  • Paragraph IV challenges
  • Tentative approvals
  • Dynamic search capabilities with data export
  • More…
See the Database Preview and Plan Comparison. Contact Us with any questions.

The above list does not discriminate between dominant and non-dominant patents. Drugs listed above may be protected by additional patents and other regulatory protections. See the DrugPatentWatch database for complete details

DISCLAIMER:
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
All trademarks and applicant names are the property of their respective owners or licensors.

If your reader cannot render the information below, go to http://www.DrugPatentWatch.com/innovation to see the latest expirations body { font-family:Calibri, tahoma, arial, sans-serif;}table { font-size:12px; font-family:Calibri, tahoma, arial, sans-serif; border-collapse:collapse; margin: 0px auto;}.xsnazzy h1, .zsnazzy h1 { margin:0; font-size:1.2em; padding:0 10px 5px 10px; border-bottom:1px solid #444; }.xsnazzy { background: transparent; margin:0 3px;}.xtop, .xbottom { display:block; background:transparent; font-size:1px; }.xb1, .xb2, .xb3, .xb4 { display:block; overflow:hidden; }.xb1, .xb2, .xb3 { height:1px; }.xb2, .xb3, .xb4 { background:#fff; border-left:1px solid #444; border-right:1px solid #444; }.xb1 { margin:0 5px; background:#444; }.xb2 { margin:0 3px; border-width:0 2px; }.xb3 { margin:0 2px; }.xb4 { height:2px; margin:0 1px;}.xboxcontent { display:block; border:0 solid #444; border-width:0 1px; height:auto; }* html .xboxcontent { height:1px; } td { padding:3px; } tr { border:.5pt; background-color:#FFF; }
Pharmaceutical Industry Intelligence

ADVERTISE HERE

This newsletter is a free service of DrugPatentWatch
DrugPatentWatch offers comprehensive details on FDA approved drugs, developers, and their patents

Simple flat-rate database subscription plans

Ultimate PlanPremium PlanBasic Plan
One year$1,995 Subscribe$1,795 Subscribe$1,095 Subscribe
One month$525 Subscribe$425 Subscribe$325 Subscribe
48 hours$95 Subscribe$75 Subscribe
Plan comparison    Site tour    Contact

Drug Patent Expirations for Jun 6 2012

TradenameApplicantGeneric NamePatent Number Patent Expiration
DILACOR XRWatson Labsdiltiazem hydrochloride5,422,123Jun 6, 2012
REQUIP XLSmithkline Beechamropinirole hydrochloride5,422,123Jun 6, 2012
SULARShionogi Incnisoldipine5,422,123Jun 6, 2012
ZYFLO CRCornerstone Therapzileuton5,422,123Jun 6, 2012

*Drugs may be covered by multiple patents or regulatory protections. See the DrugPatentWatch database for complete details.


DrugPatentWatch Serves Your Competitive Intelligence Needs

Subscribers have access to valuable datasets, including:
  • Clinical trial information
  • International patent families
  • International patent priority and PCT information
  • Patent maintenance
  • Full-text patent downloads
  • Sales data (top 200 drugs)
  • Paragraph IV challenges
  • Tentative approvals
  • Dynamic search capabilities with data export
  • More…
See the Database Preview and Plan Comparison. Contact Us with any questions.

The above list does not discriminate between dominant and non-dominant patents. Drugs listed above may be protected by additional patents and other regulatory protections. See the DrugPatentWatch database for complete details

DISCLAIMER:
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
All trademarks and applicant names are the property of their respective owners or licensors.

If your reader cannot render the information below, go to http://www.DrugPatentWatch.com/innovation to see the latest expirations body { font-family:Calibri, tahoma, arial, sans-serif;}table { font-size:12px; font-family:Calibri, tahoma, arial, sans-serif; border-collapse:collapse; margin: 0px auto;}.xsnazzy h1, .zsnazzy h1 { margin:0; font-size:1.2em; padding:0 10px 5px 10px; border-bottom:1px solid #444; }.xsnazzy { background: transparent; margin:0 3px;}.xtop, .xbottom { display:block; background:transparent; font-size:1px; }.xb1, .xb2, .xb3, .xb4 { display:block; overflow:hidden; }.xb1, .xb2, .xb3 { height:1px; }.xb2, .xb3, .xb4 { background:#fff; border-left:1px solid #444; border-right:1px solid #444; }.xb1 { margin:0 5px; background:#444; }.xb2 { margin:0 3px; border-width:0 2px; }.xb3 { margin:0 2px; }.xb4 { height:2px; margin:0 1px;}.xboxcontent { display:block; border:0 solid #444; border-width:0 1px; height:auto; }* html .xboxcontent { height:1px; } td { padding:3px; } tr { border:.5pt; background-color:#FFF; }
Pharmaceutical Industry Intelligence

ADVERTISE HERE

This newsletter is a free service of DrugPatentWatch
DrugPatentWatch offers comprehensive details on FDA approved drugs, developers, and their patents

Simple flat-rate database subscription plans

Ultimate PlanPremium PlanBasic Plan
One year$1,995 Subscribe$1,795 Subscribe$1,095 Subscribe
One month$525 Subscribe$425 Subscribe$325 Subscribe
48 hours$95 Subscribe$75 Subscribe
Plan comparison    Site tour    Contact

Drug Patent Expirations for Jun 2 2012

TradenameApplicantGeneric NamePatent Number Patent Expiration
IONSYSIncline Therapfentanyl hydrochloride6,317,629Jun 2, 2012

*Drugs may be covered by multiple patents or regulatory protections. See the DrugPatentWatch database for complete details.


DrugPatentWatch Fills Your Competitive Intelligence Needs

Subscribers have access to valuable datasets, including:
  • Clinical trial information
  • International patent families
  • International patent priority and PCT information
  • Patent maintenance
  • Full-text patent downloads
  • Sales data (top 200 drugs)
  • Paragraph IV challenges
  • Tentative approvals
  • Dynamic search capabilities with data export
  • More…
See the Database Preview and Plan Comparison. Contact Us with any questions.

The above list does not discriminate between dominant and non-dominant patents. Drugs listed above may be protected by additional patents and other regulatory protections. See the DrugPatentWatch database for complete details

DISCLAIMER:
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
All trademarks and applicant names are the property of their respective owners or licensors.

If your reader cannot render the information below, go to http://www.DrugPatentWatch.com/innovation to see the latest expirations body { font-family:Calibri, tahoma, arial, sans-serif;}table { font-size:12px; font-family:Calibri, tahoma, arial, sans-serif; border-collapse:collapse; margin: 0px auto;}.xsnazzy h1, .zsnazzy h1 { margin:0; font-size:1.2em; padding:0 10px 5px 10px; border-bottom:1px solid #444; }.xsnazzy { background: transparent; margin:0 3px;}.xtop, .xbottom { display:block; background:transparent; font-size:1px; }.xb1, .xb2, .xb3, .xb4 { display:block; overflow:hidden; }.xb1, .xb2, .xb3 { height:1px; }.xb2, .xb3, .xb4 { background:#fff; border-left:1px solid #444; border-right:1px solid #444; }.xb1 { margin:0 5px; background:#444; }.xb2 { margin:0 3px; border-width:0 2px; }.xb3 { margin:0 2px; }.xb4 { height:2px; margin:0 1px;}.xboxcontent { display:block; border:0 solid #444; border-width:0 1px; height:auto; }* html .xboxcontent { height:1px; } td { padding:3px; } tr { border:.5pt; background-color:#FFF; }
Who are the leading pharmaceutical patent challengers? A report on
Paragraph IV challenges
ADVERTISE HERE

This newsletter is a free service of DrugPatentWatch
DrugPatentWatch offers comprehensive details on FDA approved drugs, developers, and their patents

Simple flat-rate database subscription plans

Ultimate PlanPremium PlanBasic Plan
One year$1,995 Subscribe$1,795 Subscribe$1,095 Subscribe
One month$525 Subscribe$425 Subscribe$325 Subscribe
48 hours$95 Subscribe$75 Subscribe
Plan comparison    Site tour    Contact

Drug Patent Expirations for May 21 2012

TradenameApplicantGeneric NamePatent Number Patent Expiration
ACTONEL WITH CALCIUM (COPACKAGED)Warner Chilcottcalcium carbonate; risedronate sodium6,096,342*PEDMay 21, 2012
IMODIUM MULTI-SYMPTOM RELIEFMcneilloperamide hydrochloride; simethicone5,716,641May 21, 2012

*Drugs may be covered by multiple patents or regulatory protections. See the DrugPatentWatch database for complete details.


DrugPatentWatch Fills Your Competitive Intelligence Needs

Subscribers have access to valuable datasets, including:
  • Clinical trial information
  • International patent families
  • International patent priority and PCT information
  • Patent maintenance
  • Full-text patent downloads
  • Sales data (top 200 drugs)
  • Paragraph IV challenges
  • Tentative approvals
  • Dynamic search capabilities with data export
  • More…
See the Database Preview and Plan Comparison. Contact Us with any questions.

The above list does not discriminate between dominant and non-dominant patents. Drugs listed above may be protected by additional patents and other regulatory protections. See the DrugPatentWatch database for complete details

DISCLAIMER:
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
All trademarks and applicant names are the property of their respective owners or licensors.

If your reader cannot render the information below, go to http://www.DrugPatentWatch.com/innovation to see the latest expirations body { font-family:Calibri, tahoma, arial, sans-serif;}table { font-size:12px; font-family:Calibri, tahoma, arial, sans-serif; border-collapse:collapse; margin: 0px auto;}.xsnazzy h1, .zsnazzy h1 { margin:0; font-size:1.2em; padding:0 10px 5px 10px; border-bottom:1px solid #444; }.xsnazzy { background: transparent; margin:0 3px;}.xtop, .xbottom { display:block; background:transparent; font-size:1px; }.xb1, .xb2, .xb3, .xb4 { display:block; overflow:hidden; }.xb1, .xb2, .xb3 { height:1px; }.xb2, .xb3, .xb4 { background:#fff; border-left:1px solid #444; border-right:1px solid #444; }.xb1 { margin:0 5px; background:#444; }.xb2 { margin:0 3px; border-width:0 2px; }.xb3 { margin:0 2px; }.xb4 { height:2px; margin:0 1px;}.xboxcontent { display:block; border:0 solid #444; border-width:0 1px; height:auto; }* html .xboxcontent { height:1px; } td { padding:3px; } tr { border:.5pt; background-color:#FFF; }
Who are the leading pharmaceutical patent challengers? A report on
Paragraph IV challenges
ADVERTISE HERE

This newsletter is a free service of DrugPatentWatch
DrugPatentWatch offers comprehensive details on FDA approved drugs, developers, and their patents

Simple flat-rate database subscription plans

Ultimate PlanPremium PlanBasic Plan
One year$1,995 Subscribe$1,795 Subscribe$1,095 Subscribe
One month$525 Subscribe$425 Subscribe$325 Subscribe
48 hours$95 Subscribe$75 Subscribe
Plan comparison    Site tour    Contact

Drug Patent Expirations for May 15 2012

TradenameApplicantGeneric NamePatent Number Patent Expiration
COMBIVIRViiv Hlthcarelamivudine; zidovudine5,859,021May 15, 2012

*Drugs may be covered by multiple patents or regulatory protections. See the DrugPatentWatch database for complete details.


DrugPatentWatch Fills Your Competitive Intelligence Needs

Subscribers have access to valuable datasets, including:
  • Clinical trial information
  • International patent families
  • International patent priority and PCT information
  • Patent maintenance
  • Full-text patent downloads
  • Sales data (top 200 drugs)
  • Paragraph IV challenges
  • Tentative approvals
  • Dynamic search capabilities with data export
  • More…
See the Database Preview and Plan Comparison. Contact Us with any questions.

The above list does not discriminate between dominant and non-dominant patents. Drugs listed above may be protected by additional patents and other regulatory protections. See the DrugPatentWatch database for complete details

DISCLAIMER:
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
All trademarks and applicant names are the property of their respective owners or licensors.

If your reader cannot render the information below, go to http://www.DrugPatentWatch.com/innovation to see the latest expirations body { font-family:Calibri, tahoma, arial, sans-serif;}table { font-size:12px; font-family:Calibri, tahoma, arial, sans-serif; border-collapse:collapse; margin: 0px auto;}.xsnazzy h1, .zsnazzy h1 { margin:0; font-size:1.2em; padding:0 10px 5px 10px; border-bottom:1px solid #444; }.xsnazzy { background: transparent; margin:0 3px;}.xtop, .xbottom { display:block; background:transparent; font-size:1px; }.xb1, .xb2, .xb3, .xb4 { display:block; overflow:hidden; }.xb1, .xb2, .xb3 { height:1px; }.xb2, .xb3, .xb4 { background:#fff; border-left:1px solid #444; border-right:1px solid #444; }.xb1 { margin:0 5px; background:#444; }.xb2 { margin:0 3px; border-width:0 2px; }.xb3 { margin:0 2px; }.xb4 { height:2px; margin:0 1px;}.xboxcontent { display:block; border:0 solid #444; border-width:0 1px; height:auto; }* html .xboxcontent { height:1px; } td { padding:3px; } tr { border:.5pt; background-color:#FFF; }
Journal of Commercial Biotechnology

ADVERTISE HERE

This newsletter is a free service of DrugPatentWatch
DrugPatentWatch offers comprehensive details on FDA approved drugs, developers, and their patents

Simple flat-rate database subscription plans

Ultimate PlanPremium PlanBasic Plan
One year$1,995 Subscribe$1,795 Subscribe$1,095 Subscribe
One month$525 Subscribe$425 Subscribe$325 Subscribe
48 hours$95 Subscribe$75 Subscribe
Plan comparison    Site tour    Contact

Drug Patent Expirations for May 17 2012

TradenameApplicantGeneric NamePatent Number Patent Expiration
PLAVIXSanofi Aventis Usclopidogrel bisulfate4,847,265*PEDMay 17, 2012

*Drugs may be covered by multiple patents or regulatory protections. See the DrugPatentWatch database for complete details.


DrugPatentWatch Fills Your Competitive Intelligence Needs

Subscribers have access to valuable datasets, including:
  • Clinical trial information
  • International patent families
  • International patent priority and PCT information
  • Patent maintenance
  • Full-text patent downloads
  • Sales data (top 200 drugs)
  • Paragraph IV challenges
  • Tentative approvals
  • Dynamic search capabilities with data export
  • More…
See the Database Preview and Plan Comparison. Contact Us with any questions.

The above list does not discriminate between dominant and non-dominant patents. Drugs listed above may be protected by additional patents and other regulatory protections. See the DrugPatentWatch database for complete details

DISCLAIMER:
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
All trademarks and applicant names are the property of their respective owners or licensors.

If your reader cannot render the information below, go to http://www.DrugPatentWatch.com/innovation to see the latest expirations body { font-family:Calibri, tahoma, arial, sans-serif;}table { font-size:12px; font-family:Calibri, tahoma, arial, sans-serif; border-collapse:collapse; margin: 0px auto;}.xsnazzy h1, .zsnazzy h1 { margin:0; font-size:1.2em; padding:0 10px 5px 10px; border-bottom:1px solid #444; }.xsnazzy { background: transparent; margin:0 3px;}.xtop, .xbottom { display:block; background:transparent; font-size:1px; }.xb1, .xb2, .xb3, .xb4 { display:block; overflow:hidden; }.xb1, .xb2, .xb3 { height:1px; }.xb2, .xb3, .xb4 { background:#fff; border-left:1px solid #444; border-right:1px solid #444; }.xb1 { margin:0 5px; background:#444; }.xb2 { margin:0 3px; border-width:0 2px; }.xb3 { margin:0 2px; }.xb4 { height:2px; margin:0 1px;}.xboxcontent { display:block; border:0 solid #444; border-width:0 1px; height:auto; }* html .xboxcontent { height:1px; } td { padding:3px; } tr { border:.5pt; background-color:#FFF; }
FDA Orange Book archives from 2005 to
present
ADVERTISE HERE

This newsletter is a free service of DrugPatentWatch
DrugPatentWatch offers comprehensive details on FDA approved drugs, developers, and their patents

Simple flat-rate database subscription plans

Ultimate PlanPremium PlanBasic Plan
One year$1,995 Subscribe$1,795 Subscribe$1,095 Subscribe
One month$525 Subscribe$425 Subscribe$325 Subscribe
48 hours$95 Subscribe$75 Subscribe
Plan comparison    Site tour    Contact

Drug Patent Expirations for May 22 2012

TradenameApplicantGeneric NamePatent Number Patent Expiration
ACTONELWarner Chilcottrisedronate sodium6,096,342*PEDMay 22, 2012
VIRAMUNEBoehringer Ingelheimnevirapine5,366,972*PEDMay 22, 2012
VIRAMUNE XRBoehringer Ingelheimnevirapine5,366,972*PEDMay 22, 2012

*Drugs may be covered by multiple patents or regulatory protections. See the DrugPatentWatch database for complete details.


DrugPatentWatch Fills Your Competitive Intelligence Needs

Subscribers have access to valuable datasets, including:
  • Clinical trial information
  • International patent families
  • International patent priority and PCT information
  • Patent maintenance
  • Full-text patent downloads
  • Sales data (top 200 drugs)
  • Paragraph IV challenges
  • Tentative approvals
  • Dynamic search capabilities with data export
  • More…
See the Database Preview and Plan Comparison. Contact Us with any questions.

The above list does not discriminate between dominant and non-dominant patents. Drugs listed above may be protected by additional patents and other regulatory protections. See the DrugPatentWatch database for complete details

DISCLAIMER:
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
All trademarks and applicant names are the property of their respective owners or licensors.